Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples